Biogen Strikes A Deal With Isis For Antisense Technology

Biogen has agreed to pay an upfront and milestones for an option to license Isis' Phase I antisense compound to treat a rare spinal disorder.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet